1-(9H-芴-9-基)-哌嗪 | 129604-54-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 中文名称: 1-(9H-芴-9-基)-哌嗪
• 中文别名: 1-(9H-芴-9-基)哌嗪盐酸盐；哌嗪,1-(9-茀基)-
• 英文名称: 1-(9H-fluoren-9-yl)piperazine
• CAS: 129604-54-2
• 化学式: C₁₇H₁₈N₂
• mdl: MFCD00230324
• 分子量: 250.343
• InChiKey: GIIZMBGIKACGIZ-UHFFFAOYSA-N

物化性质

• 熔点：
  283-285 °C (decomp)(Solv: ethanol (64-17-5))
• 沸点：
  402.2±35.0 °C(Predicted)
• 密度：
  1.161±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.294
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  1-(9H-芴-9-基)-哌嗪 在 四氮唑 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 methyl (4-(9H-fluoren-9-yl)piperazin-1-yl)(phenyl)phosphinate
  参考文献：
  名称：

  Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth

  摘要：

  A series of fluorene-based derivatives was synthesized and evaluated for inhibiting both InhA and Mycobacterium tuberculosis growth. These compounds were inspired by the previously reported Genz-10850 molecule, a good InhA inhibitor, but with a poor activity against M. tuberculosis growth. Structure activity relationships were performed by introducing the following chemical modifications: 1) the piperazine ring; 2) the amide group; 3) the aryl moiety; and 4) the fluorene moiety. Among these new derivatives, one of them was more effective against both the InhA activity and mycobacterial growth, compared to the hit compound. Docking studies were also performed to rationalize activities of these derivatives. Furthermore, we showed for the first time that efflux pump inhibitors potentiated the efficacy of Genz-10850 (GEQ) derivatives against M. tuberculosis growth, demonstrating that these compounds could be substrates of some efflux pumps. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.06.035
• 作为产物：
  描述：

  9-羟基芴 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 6.0h， 生成 1-(9H-芴-9-基)-哌嗪
  参考文献：
  名称：

  二芳基哌嗪类化合物及其医药用途

  摘要：

  本发明涉及通式I所表示的二芳基哌嗪类化合物，其溶剂合物、立体异构体或其可药用盐，含有它们的药用组合物，以及所述化合物用于制备预防或治疗手术后疼痛、偏头痛、内脏痛、神经性疼痛等各种疼痛以及由阿片类等镇痛药物引起的成瘾性和耐受性等病症的用途。

  公开号：

  CN103130745B

文献信息

• Structure−Activity Relationship of Newly Synthesized Quinoline Derivatives for Reversal of Multidrug Resistance in Cancer
  作者：Tsuneji Suzuki、Nobuyuki Fukazawa、Kunio San-nohe、Wakao Sato、Osamu Yano、Takashi Tsuruo

  DOI：10.1021/jm960869l

  日期：1997.6.1

  interactions. Other major structural features which influence the MDR-reversing activities of these compounds are a quinoline nitrogen atom and a basic nitrogen atom in piperazine. Furthermore, in highly active compounds, the distance between the hydrophobic moiety and the basic nitrogen atom (an atom connected to 2-hydroxypropoxyquinoline) must be at least 5 A. Several compounds were found to reverse

  在体外检查了24种新合成的喹啉衍生物对肿瘤细胞多药耐药性（MDR）的影响。在低浓度下，这些化合物增强了[3H]长春新碱在K562 / ADM细胞中的积累，并逆转了肿瘤细胞MDR。结构-活性关系分析的结果表明，在高活性化合物中，疏水部分的两个芳基环偏离同一平面，因此它们能够与P-170糖蛋白（P-gp）的氢键供体相互作用pi-氢-pi相互作用。影响这些化合物的MDR-逆转活性的其他主要结构特征是哌嗪中的喹啉氮原子和碱性氮原子。此外，在高活性化合物中
• Piperazine derivatives: Synthesis, inhibition of the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase and SAR studies
  作者：Mariane Rotta、Kenia Pissinate、Anne Drumond Villela、Davi Fernando Back、Luis Fernando Saraiva Macedo Timmers、José Fernando Ruggiero Bachega、Osmar Norberto de Souza、Diógenes Santiago Santos、Luiz Augusto Basso、Pablo Machado

  DOI：10.1016/j.ejmech.2014.11.034

  日期：2015.1

  in the submicromolar range. A structure–activity relationship (SAR) evaluation indicated the importance of the chemical environment surrounding the carbonyl group for inhibition. In addition, the structure of one selected compound was supported by crystallographic studies, and experimental geometrical values were compared with semi-empirical quantum chemical calculations. Furthermore, the mode of inhibition

  在结核分枝杆菌NADH依赖性烯酰基-酰基载体蛋白还原酶（玛INHA）催化氢化物转移到长链烯酰基硫酯的底物。Mt InhA是II型分枝杆菌解离的脂肪酸生物合成系统的成员，并且是异烟肼的真正靶点，异烟肼是治疗肺结核的最处方药。在这里，合成了一系列哌嗪衍生物，并筛选了它们作为Mt InhA抑制剂，从而用IC 50鉴定了化合物值在亚微摩尔范围内。结构-活性关系（SAR）评估表明，羰基周围的化学环境对于抑制作用非常重要。此外，一种选择的化合物的结构得到晶体学研究的支持，并将实验几何值与半经验量子化学计算进行了比较。此外，确定了九种活性最高的化合物的抑制方式和抑制解离常数。这些发现表明，这9个含H-氟-9-基-哌嗪的化合物在烯酰基硫酯（2-反式-十二烯酰基-CoA）底物结合位点与Mt InhA相互作用。
• [EN] COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS ET LEURS UTILISATIONS
  申请人：UNIV VIRGINIA PATENT FOUNDATION

  公开号：WO2019005883A1

  公开（公告）日：2019-01-03

  The disclosure is directed to compounds of the formula (IA), (I)-(V) and others disclosed herein and uses of such compounds.

  该披露涉及到公式（IA）、（I）-（V）和其他在此披露的化合物，以及这些化合物的用途。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR
  申请人：Miyata Toshio

  公开号：US20090124620A1

  公开（公告）日：2009-05-14

  The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. Each symbol is defined as those in the specification.

  本发明涉及一种抑制纤溶酶原激活物抑制剂-1的抑制剂。本发明进一步涉及一种对PAI-1活性具有抑制作用的药物组合物，可用于预防和治疗与PAI-1活性相关的各种疾病的发生。此外，本发明涉及一种具有PAI-1抑制活性的新化合物，其由以下一般式（I）表示，并且其盐。每个符号的定义如规范中所述。
• Pyrrolidine Carboxamides as a Novel Class of Inhibitors of Enoyl Acyl Carrier Protein Reductase from <i>Mycobacterium tuberculosis</i>
  作者：Xin He、Akram Alian、Robert Stroud、Paul R. Ortiz de Montellano

  DOI：10.1021/jm060715y

  日期：2006.10.1

  of Mycobacterium tuberculosis, there is an urgent need to discover antituberculosis agent with novel structures. InhA, the enoyl acyl carrier protein reductase (ENR) from M. tuberculosis, is one of the key enzymes involved in the mycobacterial fatty acid elongation cycle and has been validated as an effective antimicrobial target. We report here the discovery, through high-throughput screening, of

  鉴于结核分枝杆菌的多药耐药性在世界范围内的传播，迫切需要发现具有新颖结构的抗结核药。InhA是结核分枝杆菌的烯酰基酰基载体蛋白还原酶（ENR），是分枝杆菌脂肪酸延长周期中涉及的关键酶之一，已被证实是有效的抗菌靶标。我们在此报告通过高通量筛选发现的一系列吡咯烷羧酰胺，它们是一类新的强效InhA抑制剂。与三种抑制剂复合的InhA晶体结构已用于阐明抑制剂的结合模式。通过迭代微量滴定文库合成的后续优化，然后不经纯化就地进行活性筛选，可将先导化合物的效能提高160倍以上。